Characteristic | Total, n = 116 |
---|---|
Pregnancy | |
Relapse during pregnancy, no. (%) | 13 (11.21%) |
DMT use during pregnancya, no. (%) | |
Intentionally | 6 (5.17%) |
Accidentally (at first trimester) | 38 (32.76%) |
DMT type used (Intentionally) | |
Interferon-beta | 5 (83.33%) |
DMT type used (Accidentally) | |
Interferon-beta | 15 (39.47%) |
Dimethyl fumarate | 7 (18.42%) |
Fingolimod | 12 (31.58%) |
Rituximab | 3 (7.89%) |
ocrelizumab | 1 (2.63%) |
Postpartum period | |
No. of pregnancies with postpartum relapses, no. (%) | |
0 | 85 (73.28%) |
1 | 24 (20.69%) |
2 | 5 (4.31%) |
≥ 3 | 2 (1.72%) |
Time to first postpartum relapseb, median (IQR), days | 171 (78–232) |
DMT use during postpartum year, no. (%) | |
None | 69 (59.48%) |
Interferon-beta | 22 (18.97%) |
Dimethyl fumarate | 7 (6.03%) |
Natalizumab | 3 (2.57%) |
Rituximab | 4 (3.45) |
Fingolimod | 8 (6.90%) |
Ocrelizumab | 3 (2.57%) |
Time to restart DMT after deliveryc (median, IQR), d | 86 (29–201) |